Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 102478, 7 pages
Research Article

Evaluation of 12-Lipoxygenase (12-LOX) and Plasminogen Activator Inhibitor 1 (PAI-1) as Prognostic Markers in Prostate Cancer

1Department of Urology, St' Vincent A Paulo Hospital, Wójta Radtkego 1, 81-348 Gdynia, Poland
2Department of Urology, Multidisciplinary Hospital Jantar, Rybacka 15, 82-103 Jantar, Poland
3Department of Surgical Oncology, Gdynia Oncology Center, PCK's Maritime Hospital in Gdynia, Powstania Styczniowego 1, 81-519 Gdynia, Poland
4Department of Propaedeutic Oncology, Faculty of Health Sciences, Medical University of Gdańsk, Powstania Styczniowego 9b, 81-519 Gdynia, Poland
5Department of Clinical Nutrition, Medical University of Gdańsk, Dębinki 7, 80-211 Gdańsk, Poland
6Urology Research Center, Department of Urology, The University of Toledo, Health Science Campus, Toledo, OH 43614, USA
7Protein Research Chair, Department of Biochemistry, College of Sciences, King Saud University, Riyadh 11451, Saudi Arabia
8Powiślanski College, Faculty of Health Science, 11 Listopada 13, 82-500 Kwidzyń, Poland

Received 3 January 2014; Accepted 11 February 2014; Published 24 March 2014

Academic Editor: Giovanni Luca Gravina

Copyright © 2014 Tomasz Gondek et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


In carcinoma of prostate, a causative role of platelet 12-lipoxygenase (12-LOX) and plasminogen activator inhibitor 1 (PAI-1) for tumor progression has been firmly established in tumor and/or adjacent tissue. Our goal was to investigate if 12-LOX and/or PAI-1 in patient’s plasma could be used to predict outcome of the disease. The study comprised 149 patients (age ) divided into two groups: a study group with carcinoma confirmed by positive biopsy of prostate () and a reference group () with benign prostatic hyperplasia (BPH). The following parameters were determined by the laboratory test in plasma or platelet-rich plasma: protein level of 12-LOX, PAI-1, thromboglobulin (TGB), prostate specific antigen (PSA), C-reactive protein (CRP), hemoglobin (HGB, and hematocrit (HCT), as well as red (RBC) and white blood cells (WBC), number of platelets (PLT), international normalized ratio of blood clotting (INR), and activated partial thromboplastin time (APTT). The only difference of significance was noticed in the concentration of 12-LOX in platelet rich plasma, which was lower in cancer than in BPH group. Standardization to TGB and platelet count increases the sensitivity of the test that might be used as a biomarker to assess risk for prostate cancer in periodically monitored patients.